Sector News

Novartis buys 12.8 percent stake in BioLineRX in co-development deal

December 17, 2014
Life sciences
(Reuters) – Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.
 
Under the agreement, Novartis, which invested an initial $10 million, will evaluate projects presented by BioLineRX for development and future licensing, the Israeli firm said in a statement. They hope to develop up to three clinical projects.
 
Novartis acquired an initial 5 million American depositary shares of BioLineRx in a private transaction at $2.00 a share.
 
The partnership will be transformative for BioLineRX, said Chief Executive Kinneret Savitsky, and will give Novartis, one of the world’s largest pharmaceutical companies, access to Israeli research institutions, hospitals and biotech start-ups.
 
Once a project is selected, Novartis will pay BioLineRx an option fee of $5 million and fund half the remaining development costs in the form of an additional equity investment in BioLineRx.
 
The companies agreed to limit how big a share Novartis can buy of BioLineRX, but the amount was not disclosed, a BioLineRX spokeswoman said.
 
Novartis will have an exclusive right of first negotiation to license from BioLineRx each project.
 
(Reporting by Ari Rabinovitch; Editing by Tova Cohen and David Holmes)

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend